CHEPLAPHARM Arzneimittel GmbH has successfully gained a foothold in the US American institutional bond market.

Die CHEPLAPHARM Arzneimittel GmbH hat erfolgreich auf dem US-amerikanischen Markt für institutionelle Anleihen Fuß gefasst.

CHEPLAPHARM Arzneimittel GmbH Announces Pricing of €575 Million 4.375% Senior Secured Notes due 2028 $500 Million 5.500% Senior Secured Notes due 2028

CHEPLARPHARM announces that it is in advanced negotiations to acquire additional marketing authorizations and intellectual properties for additional territory not yet owned by us for one of our…

CHEPLAPHARM Arzneimittel GmbH Announces Offering of €1,000,000,000 (equivalent) Senior Secured Notes due 2028

CHEPLARPHARM announces the acquisition of two product portfolios from LeoPharma and Takeda

Greifswald, 06/22/2020

Greifswald, 22.06.2020

Greifswald, 15.05.2020 – Zum zweiten Mal in Folge wird das Greifswalder Familienunternehmen CHEPLAPHARM Arzneimittel GmbH mit dem begehrten „Axia Best Managed Companies Award“ ausgezeichnet und…

Cheplapharm Arzneimittel GmbH - Quarterly Update Call Q4 / FY 2019 | Wednesday, 08 April 2020, 10:30 BST | 11:30 CEST